Digital Building Materials DataBM. Com, Qibin Group intends to invest 780 million yuan to build two production lines of neutral borosilicate pharmaceutical glass tubes in Luxian Economic Development Zone, Luzhou City, Sichuan Province, and newly register "Sichuan Qibin Pharmaceutical Materials Science and Technology Co., Ltd." (Tentative name, subject to the final approval of the industrial and commercial registration authority) to be responsible for the project operation.
The announcement shows that the project is financed by Fujian Pharmaceutical Material Science and Technology Co., Ltd., a holding subsidiary of Qibin Group, and the proposed scale is two 50 t/d four-line neutral borosilicate pharmaceutical glass tube production lines.
Qibin Group said that the company's pharmaceutical glass products are positioned as high-end pharmaceutical glass. At present, two production lines, 25 t/d and 40 t/d, have been put into production in Chenzhou, Hunan Province. After more than one year of operation, the company's current technology has gradually matured, and the product performance indicators are leading the country and international. The new production line will fully absorb the existing experience and technology, and lead the existing domestic products in water resistance, acid resistance, impact resistance and other indicators.
Expanded reading:
International neutral pharmaceutical glass is commonly known as Class I glass. It is also called 5.0 glass in China (the expansion coefficient of the average linear thermal expansion coefficient α = (4.6 ~ 5.8) × 10-6 K-1 in the range of 20 ~ 300 ° C is 5.0) or Grade A material. Compared with low borosilicate glass and soda-lime glass, medium borosilicate glass bottle has good thermal and chemical stability, high hardness, good wear resistance, long service life and high thermal conductivity, which is the preferred material in the field of pharmaceutical packaging. At present, neutral borosilicate pharmaceutical glass has been widely recognized in the international pharmaceutical packaging market for its excellent performance, and has been widely used in the field of pharmaceutical packaging, especially suitable for containing biological products, blood products, freeze-dried preparations, vaccines and other high value-added drugs and special drugs with high PH value.
With the growth of China's medical and health undertakings and the implementation of the strategy of healthy China, medical and health requirements are constantly improving with the improvement of people's quality of life, and the pace of internationalization of the pharmaceutical industry is accelerating. China's pharmaceutical industry is facing unprecedented challenges and golden opportunities for development. With the promotion of policies such as consistency evaluation, related review and approval, and purchasing with quantity, China's pharmaceutical industry is constantly upgrading, the requirements for pharmaceutical packaging are also constantly improving, and the substitution process of neutral pharmaceutical glass is accelerating. The consistency evaluation policy issued by the State Food and Drug Administration in 2017 clearly requires that the packaging materials used for generic drugs should be consistent with the original drugs, and all drugs for water injection should use neutral borosilicate glass; the State Food and Drug Administration in 2020 requires that the quality and performance of packaging materials and containers used for injection should not be lower than that of reference preparations, so as to ensure that the quality of drugs is consistent with that of reference preparations. The promulgation of the above policies will further accelerate the upgrading of pharmaceutical glass products, that is, gradually transforming from soda-lime glass and low borosilicate glass to medium borosilicate glass, and the substitution ratio of medium borosilicate glass will increase year by year. According to the international Reportlinker report, the global pharmaceutical glass market will reach $22.05 billion in 2025, the growth rate of emerging markets in India and China will reach 9%, and China will become one of the major consumers of pharmaceutical glass packaging bottles. The 5.0
neutral glass series includes colorless and amber glass tubes for use in the production of syringes, cartridge and pen systems, ampoules, and vials for pharmaceutical packaging.
浙公网安备33010802003254号